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1 
 
Despite the increasing evidence of a possible interaction between adolescent Cannabis 
abuse and the subsequent development of psychiatric disorders, Cannabis remains the 
illicit drug most abused by adolescents.  
We have previously demonstrated that female rats chronically treated during 
adolescence with increasing doses of delta-9-tetrahydrocannabinol (THC), the main 
psychoactive ingredient of cannabis, develop a depressive/psychotic-like phenotype in 
adulthood. Interestingly, only chronic adolescent exposure to THC, but not adult 
exposure, led to this complex phenotype, suggesting that adolescence may represent a 
more vulnerable period for the adverse effect of THC. However, the neurobiology of this 
vulnerability is not still clear. 
Considering the important role assumed by epigenetics in the etiopathogenesis of 
psychiatric disorders, the main goal of this thesis is to extend our knowledge on the 
impact of adolescent THC exposure on histone modifications occurring in other brain 
areas involved in the different aspects of the depressive/psychotic-like phenotype 
described in our animals. Specifically, we considered the Hippocampus for its involvement 
in cognition, the Nucleus Accumbens for its role in the reward circuit, and the Amygdala 
for its relevance in the emotional behaviour. To investigate the existence of age-
specificity of THC effects, we performed the same analysis also after adult THC treatment. 
To investigate sex-dependency of THC response, we also checked THC response in 
adolescent male animals. 
First of all, adolescent (PND 35-45) and adult (PND 75-85) female Sprague-Dawley rats 
were treated twice a day with increasing intraperitoneal (ip) doses of THC: 2.5 mg/kg, 5 
mg/kg, and 10 mg/kg or with its vehicle. Two, 24 and 48 hours after the end of the 
treatment, the brain areas of interest were collected and. Histone modifications 
associated with both transcriptional repression (H3K9 di- and tri-methylation, H3K27 
trimethylation) and activation (H3K9 and H3K14 acetylation) were evaluated.  
Chronic THC exposure affected histone modifications in the brain of female rats in a 
region- and age-specific manner. Indeed, THC acted on different targets depending on 
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the considered brain areas and, remarkably, the adolescent brain was generally more 
sensitive to THC exposure compared to the adult one. Specifically, in the Hippocampus of 
adolescent rats, THC induced a reduction of H3K14ac levels 2 hours after the end of the 
treatment. This was followed by a significant increase in di- and tri-methylation of H3K9 
at 24 hours. Regarding the Nucleus Accumbens, H3K9me3 was significantly increased 2 
hours after the end of the treatment. This enhancement was maintained 24 hours later, 
and it was paralleled by a significant increase in H3K9me2 and H3K14ac levels. On the 
contrary, at 48h, H3K9me3 levels, as well as H3K9me2 and H3K14ac levels were 
significantly reduced. In the Amygdala, THC administration induced a significant increase 
in H3K9me2 levels 2 hours after the end of the treatment. Twenty-four hours later, while 
this alteration returned to control values, H3K9me3 levels were significantly enhanced.  
Adult female rats exposed to chronic THC showed a different pattern of histone 
alterations. In the Hippocampus and Nucleus Accumbens, H3K14 acetylation levels were 
significantly increased, respectively, 2 and 24 hours after the end of the treatment. 
Intriguingly, a more complex picture is present in the adult Amygdala, in which a 
significant decrease in H3K9me2 and H3K27me3 were induced immediately after the 
cease of the treatment. Twenty-four hours later H3K9ac was significantly reduced, and at 
48 hours, H3K14ac levels were significantly decreased. 
As a whole, the investigation performed in female rats suggests that in the adolescent 
brain THC induced a primary effect represented by changes leading to transcriptional 
repression, whereas the primary effect induced by adult THC exposure led to 
transcriptional activation. Interestingly, only in the adolescent brain, the primary effect 
was followed by a homeostatic response to counterbalance the THC-induced repressive 
effect, except in the amygdala. The presence of a more complex response in the 
adolescent brain may be part of the mechanisms that make the adolescent brain 
vulnerable to THC adverse effects. 
The second aim of this thesis was to extend our knowledge on the impact of adolescent 
THC exposure on histone modifications occurring in different brain areas of male rats. To 
this aim, adolescent (PND 35-45) male Sprague-Dawley rats were treated with the same 
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protocol previously described for females and we conducted the same analysis in the 
Prefrontal Cortex, Hippocampus and Nucleus Accumbens. 
Chronic THC exposure affected histone modifications in the brain of male rats in a region- 
specific manner. Surprisingly, in the Prefrontal cortex and Hippocampus, we did not found 
any histone alterations at any intervals of time, and only in the Nucleus Accumbens we 
found significant alterations in H3K9me3 levels. Specifically, H3K9me3 was decreased 
immediately after the end of the treatment and then increased 24h later.  
Further studies are needed to clarify the epigenetic landscape in the brain of male rats 
and how it could account for the development of the psychotic-like phenotype described 
in these animals. 
However, it is possible to conclude that Cannabis abuse during adolescence could impair 
the brain network functionality acting through a mechanism involving histone 
modifications that is characterized by sex-specificity.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
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THE ENDOCANNABINOID SYSTEM 
 
The discovery in 1990 that a 473-amino-acid G-protein coupled receptor encoded by a rat 
brain cDNA clone mediated the effects of Δ9-tetrahydrocannabinol (THC), the main 
psychoactive component present in Cannabis Sativa, represented the starting point for 
the identification and characterization of the now known as endocannabinoid system 
(ECS). 
The term “endocannabinoid system” refers to a lipid signalling system characterized by 
specific receptors, their endogenous lipid ligands called endocannabinoids, [the best 
known are N-arachidonoylethanolamide (anandamide, AEA) and 2-arachidonoylglycerol 
(2-AG)], and the associated enzymatic machinery (transporters, biosynthetic and 
degradative enzymes) involved in the synthesis and degradation of endocannabinoids. 
Based on the intense research carried out in the last decades, it is known that the ECS is 
implicated in the modulation of numerous physiological functions and pathological 
conditions not only in the central nervous system (CNS) but in the entire organism. 
 
CANNABINOID RECEPTORS 
 
 
 
 
 
 
 
 
Figure 1.Stucture of cannabinoid receptors (CB1 and CB2) 
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The first sequenced and cloned cannabinoid receptor, called CB1R, (Matsuda et al., 1990), 
is located mainly presynaptically and widely distributed in different regions of the central 
nervous system (Fig.1).  
In particular, it is present in high density in the basal ganglia, cerebellum, hippocampus, 
and cerebral cortex (Herkenham et al., 1991). Moreover, it is also observed from 
moderate to low densities in the Amygdala, Nucleus accumbens, Hypothalamus, 
Midbrain, Medulla oblongata, and Spinal cord. Finally, CB1 is present at lower levels in 
peripheral tissues such as the liver, adipose tissue, exocrine pancreas, skeletal muscles, 
gastrointestinal tract, and immune cells. It belongs to the superfamily of G protein 
coupled receptors, which have seven transmembrane segments connected by three 
extracellular and three intracellular loops, an extracellular N-terminal tail, and an 
intracellular C-terminal tail. CB1 receptor is mostly associated with Gi and Go. 
Consequently, its activation (i) inhibits adenylyl cyclase activity reducing cAMP levels, (ii) 
stimulates the mitogen activated protein kinases (MAPK) pathway (iii) modulates the 
activation of potassium channel of type A and “inward rectifier”, and (iv) inhibits N and 
P/Q type calcium currents (Iannotti et al., 2016). Some studies have shown that CB1 in 
certain cell types can regulate adenylyl cyclase (AC) also via Gs or Gq (Turu et al., 2010), 
or be coupled, via Gi/o or Gq/11, to other types of intracellular signals, such as the protein 
kinase B (Akt/PKB), phosphoinositide 3-kinase (PI3K) and phospholipase C/inositol 1,4,5-
trisphosphate/protein kinase C (PLCβ/IP3/PKC) pathways (Navarrete et al.,2010; Gómez 
del Pulgar et al., 2000). 
Within the brain, CB1 receptors are expressed on GABAergic, glutamatergic, serotonergic, 
noradrenergic, and dopaminergic terminals (Azad et al., 2008; Hermann et al., 2002; Kano 
et al., 2009; Morozov et al., 2009; Oropeza et al., 2007), but given the relative abundance 
of excitatory and inhibitory neurons in the brain, and the high levels of CB1 receptor 
expression on these terminals, the predominant effects of eCB signalling occur at 
GABAergic and glutamatergic synapses (Katona and Freund, 2012). Finally, CB1 receptor 
is also found in non-neuronal cells of the brain, particularly in astrocytes, where its 
activation promotes the release of neurotransmitters (Stella, 2010; Oliveira da Cruz et al., 
2015). Overall, CB1 receptor is the most abundant GPCR in the brain. 
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The function of the CB2 receptor is often related to that of CB1 receptor, even though its 
protein sequence shows only 44% homology to that of its cognate receptor (Fig1). CB2 
receptors were cloned a few years after CB1R, and initially, their localization was thought 
to be restricted to peripheral tissues and in particular to immune tissues where they 
modulated cell migration and cytokine release (Klein et al., 1995; Schatz et al., 1997). It is 
known that CB2Rs are located in the spleen, liver, lungs, gastrointestinal tract, and 
adipocytes as well as in cardiac and bone tissue. In contrast to CB1, CB2 levels in the brain 
are very low, and emerging studies have shown that its expression has been found mostly 
in activated microglia, especially during inflammatory and neurodegenerative processes. 
The presence of CB2 receptors in neuronal cells is still under debate (Stella, 2010; Pertwee 
et al., 2010; Di Marzo, 2009). Similar to CB1, CB2 is a GPCR and is coupled to Gi proteins. 
Therefore, its activation induces adenylyl cyclase inhibition and MAP kinase pathway 
activation. However, it does not present any effect on voltage-gated ion channels.  
 
OTHER “CANNABINOID” RECEPTORS  
 
Although the International Union of Basic and Clinical Pharmacology recognized CB1 and 
CB2 as the only cannabinoid receptors, recent research shows that the orphan G protein 
receptor GPR55 could be considered a potential cannabinoid receptor. The endogenous 
ligand of this receptor is lysophosphatidylinositol (LPI) (Oka et al., 2007; Sharir et al., 
2012), but GPR55 seems to be activated by Δ9-THC as well as by some synthetic inverse 
agonists of CB1 receptors, and antagonized by the other major, nonpsychotomimetic 
phytocannabinoid, cannabidiol (CBD). Contrasting data exist regarding the possibility that 
low concentrations of endocannabinoids also activate GPR55 (Sharir et al., 2012; Pertwee, 
2007), and such controversies might be due either to biased signalling of these molecules 
at this receptor, depending on the cell type and conditions used for the assay, or to the 
recently discovered formation of heteromers between GPR55 and CB1 (Kargl et al., 2012; 
Martínez-Pinilla et al., 2014).This receptor is couplrd to Gq and G12/13 proteins, 
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therefore it activates the phospholipase C and small GTPase family proteins, among which 
RhoA is present. 
Another atypical cannabinoid receptor is the transient receptor potential vanilloid type 1 
(TRPV1) receptor. The endocannabinoid anandamide, but not 2-arachidonoylglycerol, 
binds to a cytosolic site of the receptor increasing intracellular calcium concentration, (Di 
Marzo and De Petrocellis, 2012). However, anandamide affinity is lower than that 
observed for CB1 and CB2 receptors. 
Finally, it has been demonstrated that AEA and its congeners are able to activate 
peroxisome proliferator-activated receptors (PPAR) alfa and gamma. This action could 
mediate, at least in part, some of the biological effects of these compounds, such as 
regulation of glucose and lipid metabolism as well as inflammatory responses. This 
activity could also explain the antidepressant and antiepileptic effectiveness of AEA and 
its congeners that has been shown in some preclinical and clinical studies. 
 
ENDOGENOUS LIGANDS 
 
 
 
 
 
 
 
Figure 2. N-arachidonoylethanolamine (AEA), 2-Arachidonoylglycerol (2-AG) 
 
The discovery of these two receptors immediately suggested the hypothesis of the 
existence of their endogenous ligands, or, as defined later, “endocannabinoids” (Fig2). 
Thus, in 1992, the first endogenous agonist of both cannabinoid receptors was isolated 
from the pig brain, identified as N-arachidonoyl-ethanolamine (AEA) and named 
anandamide from the Sanskrit word ananda for “bliss” (Devane et al., 1992). Three years 
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later, a second ligand of both cannabinoid receptors was isolated from the canine gut and 
turned out to be a common intermediate in phospholipid and triglyceride metabolism, 
i.e. 2-arachidonoyl-glycerol (2-AG) (Mechoulam et al., 1995).  
AEA is a derivative of arachidonic acid (AA) and ethanolamine. This endocannabinoid 
behaves as an agonist of CB1 and the affinity of this compound for CB2 is far less than for 
CB1 (Pacher et al., 2006; Lambert and Fowler, 2005). The concentration of AEA in the brain 
is very low since this endocannabinoid is synthesized on demand from a phospholipidic 
precursor present in the cell membrane. Higher levels of AEA in the brain are found in 
areas where there is a high density of CB1 receptors, such as hippocampus and cerebral 
cortex (Felder et al., 1996). 
2-AG is an ester of glycerol. Since it was firstly isolated in the dog intestine and pancreas, 
it was considered a peripheral ligand (Mechoulam et al., 1995). Later on it was identified 
in the brain where it was found at a higher concentration than AEA (Sugiura et al., 1995).  
Recently, other ECs have also been proposed during the last years, including 2-
arachidonylglycerol ether (noladin ether), N-arachidonoyl-dopamine (NADA), and 
virodhamine, but their pharmacological activity and metabolism have not yet been 
thoroughly investigated. Two AEA-related compounds, i.e. N-oleoylethanolamine (OEA) 
and N-palmitoylethanolamine (PEA), have been included in an “extended” ECS. Although 
these two latter molecules lack strong affinity for either CB1 or CB2 receptors, they are 
biosynthetized by the same class of enzymes for AEA (Iannotti et al., 2016) 
 
 
ENDOCANNABINOID-BIOSYNTHETIC AND CATABOLIC PATHWAYS 
 
It is generally accepted that endocannabinoids are synthetized mainly “on demand” by 
stimulus-dependent cleavage of membrane phospholipid precursors following elevation 
of intracellular calcium (Piomelli, 2003). However, recent data suggest the existence of a 
storage system also for these mediators, according to which endocannabinoids are 
secreted from microglial cells through extracellular membrane vesicles (known as 
exosomes)(Gabrielli et al., 2015). In general, endocannabinoids do not share the same 
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metabolic or biosynthetic pathways; indeed, distinct regulatory mechanisms for AEA and 
2-AG have been demonstrated (Ligresti et al., 2016). 
 
SYNTHESIS 
AEA (Fig.3) is produced by the cleavage of a phospholipid precursor, the N-arachidonoyl-
phosphatidylethanolamine (NAPE), through at least three different pathways: the most 
direct one is catalysed by an N-acyl-phosphatidylethanolamine-selective phospholipase D 
(NAPE-PLD) (Okamoto et al., 2009), localized in the inner layer of cell membrane. 
Alternative pathways include the formation of phospho-AEA from hydrolysis of NArPE 
catalyzed by phospholipase C enzyme(s), followed by its conversion into AEA by protein 
tyrosine phosphatase PTPN22; or the conversion of NArPE into 2-lyso-NArPE by a soluble 
form of phospholipase A2, followed by the action of a lysophospholipase D.  
The biosynthesis of 2-AG (Fig3.) appears to occur almost exclusively via diacylglycerol 
(DAG) hydrolysis by either of two sn-1-specific diacylglycerol lipases (DAGL) alpha or beta, 
the alpha-isoform being more important in the adult brain (Ligresti et al., 2016). 
 
RELEASE AND UPTAKE  
In the brain, after biosynthesis, endocannabinoids are released from the post-synaptic 
neuron, cross the synapse as retrograde messengers, and bind to CB1Rs expressed pre-
synaptically, thus inhibiting neurotransmitter release. Due to their lipophilic nature, 
endocannabinoids can diffuse through the plasma membrane, if their levels in the 
extracellular space are higher than their intracellular concentration. (Ligresti et al., 2016).  
The intracellular sequestration of endocannabinoids by intracellular proteins has also 
been suggested as a mechanism for endocannabinoids transport in the cytoplasm (Hillard 
and Jarrahian, 2005): Hsp70, FABP5 and FABP7 are reported to be anandamide 
intracellular binding proteins, being responsible for intracellular sequestration of AEA 
(Kaczocha et al., 2009; Oddi et al., 2009).  
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DEGRADATION 
After reuptake, endocannabinoids may be degraded by their metabolic enzymes into 
molecules that can be recycled and used to synthesize new endocannabinoids or other 
endogenous compounds or may be converted into metabolites that may have biological 
activity, interfering with cell homeostasis. AEA is primarily degraded by FAAH (Fig 3) 
through hydrolysis into arachidonic acid and ethanolamine (Cravatt et al., 1996) but since 
it presents structural similarities with polyunsatured fatty acids, it can also serve as 
substrate for the inducible cyclooxygenase-2 (COX-2) (Ross, 2003). The molecular 
mechanism underlying 2-AG hydrolysis appears more complicated than AEA. Although 
FAAH can also degrade 2-AG into glycerol and arachidonic acid (Goparaju et al., 1998) the 
main enzyme responsible for its inactivation is monoacylglycerol lipase (MAGL) (Dinh et 
al., 2002), a cytosolic enzyme belonging to the serine hydrolase superfamily (Lambert and 
Fowler, 2005). The development of MAGL inhibitors has been reported to raise brain 2-
AG levels (Makara et al., 2005). However, the evidence that microglial cells hydrolyze 2-
AG even in the absence of MAGL (Muccioli et al., 2007) as well as immunodepletion 
experiments strongly suggest the existence of additional 2-AG-hydrolyzing enzymes other 
than MAGL. Indeed, recent data have shown that other enzymes such as ABHD6 (Marrs 
et al., 2010) and ABHD12, (Blankman et al., 2007), are also involved in 2-AG hydrolysis. 
 
 
 
 
 
 
 
 
 
 
Figure 3. Synthesis, inactivation and oxidation of AEA and 2-AG (Iannotti et al., 2016) 
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CANNABIS AND ADOLESCENCE 
 
Cannabis continues to dominate the world’s illicit drug markets in terms of pervasiveness 
of cultivation, volume of production and number of consumers. Indeed in 2017, UNODC 
estimates that 183 million people (3.8% of the global population aged 15-64) used 
Cannabis (United Nations Office on Drugs and Crime, 2017). The main psychoactive 
constituent of Cannabis is delta-9-tetrahydrocannabinol (THC), which was isolated by 
Gaoni and Mechoulam in 1964 (Gaoni and Mechoulam, 1964). In the plant, THC is mainly 
found at the level of female inflorescences. Over the last two decades, the percentage of 
this compound in Cannabis has increased from 4% to 12% in the United States (ElSohly et 
al., 2016). Following Cannabis consumption, the subject may switch between moments 
of relaxation and euphoria with perceptual alterations including temporal, auditory, and 
visual distortion, as well as decline in cognitive functions. Furthermore, it is possible to 
find significant physiological alterations associated with cannabis use, such as heart rate 
increase, conjunctival hyperaemia, dry mouth, and appetite stimulation. The 
pharmacological action of THC mainly depends on its binding with CB1 receptor (Howlett, 
2002; Matsuda et al., 1990, 1992). 
Despite the increasing evidence of a possible relationship between adolescent Cannabis 
abuse and the later development of psychiatric disorders (Di Forti et al., 2014; Wilkinson 
et al., 2014), Cannabis remains the most widely used illicit drug among adolescents. 
According to NIDA report in 2017, 45% of adolescents (aged 12-19) tried Cannabis in their 
lifetime and 5.90% of them used it daily (National Institute on Drug Abuse, 2017). The 
high prevalence of its use and the evolving policy surrounding the legalization of cannabis 
in the western countries predicts an increasing amount of young people suffering from 
psychiatric disorders related to Cannabis exposure in the next future. Therefore, there is 
an urgent need to elucidate the molecular underpinnings that link adolescent Cannabis 
consumption to the development of mental illnesses later in life. 
Adolescence is the period between childhood and adulthood, encompassing not only 
reproductive maturation, but also cognitive, emotional and social maturation. The 
adolescent brain is a brain in transition that differs anatomically and neurochemically 
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from that of the adult. During adolescence, the brain undergoes intense structural 
remodelling (Gogtay and Thompson, 2010; Paus, 2010) in which the endocannabinoid 
system seems to play a crucial role due to its modulatory activity (Galve-Roperh, 2009; 
Rubino et al., 2015). Despite the fact that the brain reaches its maximum size around 5 
years of age, essential maturation processes that include myelinisation, synaptic 
refinement and volume reduction of grey matter, continue to occur during adolescence 
extending well into young adulthood (Blakemore, 2013; Whitford et al., 2007; Cohen-
Cory, 2002; Katz and Shatz, 1996; Luna, 2009). These changes lead to functional and 
structural increases in connectivity and integrative processing, and a modification in the 
balance between limbic/subcortical and frontal lobe functions (Giedd, 2008). The 
perfectly orchestrated occurrence of all these dynamic changes is fundamental for 
attaining a correctly shaped adult brain. Any interference with these developmental 
processes might represent a risk factor for mental disease (Spear, 2000; Rubino and 
Parolaro, 2016). Adolescence is also the period in which drug consumption begins, 
especially Cannabis use, and it is known that chronic consumption of drugs of abuse 
induces important changes in the brain, mainly in the mesocorticolimbic circuitry (Koob 
and Volkow, 2016). Moreover, recent studies demonstrated the active and dynamic 
nature of development of the endocannabinoid system during the adolescent period 
(Rubino and Parolaro, 2016), together with the suggestion that the endocannabinoid tone 
could play a role in the elimination of excitatory synapses and thus in pruning processes. 
Therefore, it is possible to hypothesize that heavy use of Cannabis, during adolescence 
might interfere with the physiological role played by the endocannabinoid system in 
adolescent neuronal remodelling thus leading to altered brain maturation. 
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LONG TERM EFFECTS INDUCED BY ADOLESCENT CANNABIS ABUSE 
IN HUMANS 
 
Cannabis is the illegal drug most consumed by adolescents and Cannabis use among this 
population has been accompanied by a decrease in the age of first use in the last years. 
Even if the majority of abusers does not report adverse reactions, an increasing number 
of epidemiological studies seems to suggest that sustained Cannabis use during 
adolescence may increase the risk for developing cognitive deficits, psychosis, depression, 
and may act as a gateway to other drugs of abuse. 
 
COGNITIVE ASPECTS 
 
Regular use of Cannabis during puberty has a negative impact on memory, learning, and 
attention (Blakemore, 2013). Several case-control and longitudinal studies have provided 
evidence of an association between adolescent Cannabis exposure and poorer 
educational performances (Fergusson et al., 2003; Silins et al., 2014; Townsend et al., 
2007). Some data suggest that even adult Cannabis consumers have a negative impact on 
memory, however they can regain their cognitive performances, reaching almost the 
control levels, through an appropriate and prolonged period of abstinence. This same 
improvement does not occur in adolescent abusers who still present cognitive deficits 
even months after the end of Cannabis use (Medina et al., 2007). The precise mechanism 
through which Cannabis induces negative effects on cognitive functions has not been 
entirely clarified yet; nevertheless, recent research has demonstrated a close association 
between the chronic use of Cannabis during adolescence and anatomic and/or functional 
brain alterations. These alterations may include hippocampal asymmetry, aberrant 
activation of some signal transduction pathways in different cerebral regions, and 
changes in white matter microstructures (Jacobus and Tapert, 2013). 
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EMOTIONAL ASPECTS 
 
Several studies have revealed a link between adolescent Cannabis exposure and 
depression, especially in female subjects (Chadwick et al., 2013; Lee et al., 2008). The 
amount of drug consumed seems to be relevant; indeed, the risk for developing 
depressive disorders occurs only in habitual Cannabis abusers (Van Laar et al., 2007). 
Furthermore, if the use begins before the age of 17, the resulting risk is even higher 
(Hayatbakhsh et al., 2007). It seems therefore clear that a continuative and premature 
use of Cannabis is associated with an increased risk of developing depression, especially 
among female abusers. 
 
PSYCHOTIC SYMPTOMS  
 
Epidemiological studies have shown that the use of Cannabis during adolescence 
increases the risk of later development of psychotic symptoms (Chadwick et al., 2013). 
The association between Cannabis abuse and the subsequent development of psychosis 
seems to be related to the age at which drug consumption begins (Arseneault et al., 
2002). Moreover, the lower the age of the first exposure to Cannabis, the earlier the onset 
of psychotic symptoms, especially in frequent smokers of enriched THC strains, such as 
skunk (Di Forti et al., 2014). The reason why major effects are observed in those who 
started Cannabis abuse earlier is still unclear. Nevertheless, it is well known that 
significant cerebral modifications occur during adolescence and the abuse of drugs during 
this period of life may influence cerebral circuit maturation, affecting brain functionality. 
These functions include reward and decisional processes, attention, learning and 
memory, and behavioural control. Since the ECS may play a role in the adolescent brain 
maturation, the use of Cannabis in this critical period might affect maturation processes, 
thus increasing the risk of psychosis. However, not all Cannabis abusers will develop 
psychosis, thus suggesting the importance of factors of vulnerability with which Cannabis 
consumption can interact. These factors may include genetic susceptibility (such as the 
15 
 
Val108Met polymorphisms of COMT, or Val66Met polymorphisms for BDNF, with the 
female population carrying Met variant more at risk of early psychosis), along with 
environmental factors (such as adverse experiences during childhood) (Chadwick et al., 
2013; Decoster et al., 2011; Henquet et al., 2008). 
 
LONG TERM EFFECTS INDUCED BY ADOLESCENT CANNABIS ABUSE 
IN ANIMAL MODELS  
 
Epidemiologic data provide evidence that Cannabis exposure in adolescence is an 
important contributing factor to psychiatric vulnerability; however, the molecular 
mechanisms underlying this association are poorly understood. The use of animal models 
may be considered an alternative strategy in order to successfully evaluate the link 
between Cannabis abuse and the development of psychiatric disorders. Indeed, animal 
models of early Cannabis exposure represent a unique tool to characterize the long-
lasting behavioural consequences of Cannabis use and to clarify the underlying cellular 
mechanisms.  
The experimental studies that assess long-term effects induced by chronic cannabinoid 
treatment during adolescence are relatively few and have sometimes shown conflicting 
results, probably due to differences in the parameters used in the studies (rat strain, 
cannabinoid agonist, and dose administered). Overall, existing data show the presence of 
subtle changes in adult cerebral circuits following cannabinoid treatment in adolescence. 
These changes are known to affect cognitive and emotional processes, thus they may 
contribute to the development of the alleged psychiatric disorders ensuing from 
adolescent cannabinoid exposure. 
 
COGNITIVE ASPECTS 
 
In rodents, chronic administration with either synthetic or natural cannabinoids during 
adolescence induces recognition memory deficits that are evident from 15 days to 30 days 
after discontinuing the treatment (O’Shea et al., 2004, 2006; Quinn et al., 2008; Realini et 
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al., 2011; Schneider and Koch, 2003; Zamberletti et al., 2014). This alteration is present in 
both female and male rats, but it does not appear when the treatment is performed in 
adult rats (Renard et al., 2013; Realini et al., 2011). Moreover, in the spatial version of the 
object recognition task, Abush and Akirav (2012) found that chronically treated rats 
showed impairment in short-term memory evident up to 75 days after the last injection. 
Similarly, spatial working memory deficits (tested by the eight-arm radial maze) were 
described after adolescent THC exposure in adult rats (Rubino et al., 2009a, 2009b). A 
persistent THC effect selective for spatial working memory was also observed under well-
controlled experimental conditions in adolescent monkeys (Verrico et al., 2014). Finally, 
adult animals exposed to WIN 55,212-2 in adolescence showed impairments in the 
attentional set-shifting task and thus in cognitive flexibility (Gomes et al., 2014). When 
pure spatial learning was assessed in the Morris Water Maze, researchers found no effect 
of the adolescent exposure to natural or synthetic cannabinoids, in both male and female 
rats (Cha et al., 2006, 2007; Higuera-Matas et al., 2009). No effect was also observed when 
aversive memory was monitored (Rubino et al., 2009a, 2009b). These findings suggest 
that adolescent cannabinoid exposure may impair specific components of memory, and 
more likely the forms of memory where PFC plays a role. 
 
EMOTIONAL ASPECTS  
 
There is evidence that adolescent cannabinoid exposure alters emotional regulation in 
adulthood, although these results vary depending on the particular index or process 
examined. 
Contrasting data were reported regarding anxiety monitored in the elevated plus maze 
or open field test. Some authors reported no changes in the anxiety profile of animals 
pre-treated with cannabinoid compounds during adolescence, whereas others described 
an anxiolytic or even an anxiogenic effect (Rubino and Parolaro, 2016). A stronger 
agreement exists about social anxiety: all the authors who studied sociability after 
adolescent exposure to cannabinoids found an impairment in social behaviours, and 
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reduction in social interaction has been considered as an anxiogenic behaviour in rodents 
(File and Hyde, 1978). Thus, it appears that depending on the test used, cannabinoids may 
differently affect the anxiety profile, inducing anxiolytic or anxiogenic effects. However, 
it is worth noting that often results in the social interaction test do not correlate with 
performance in other animal tests of anxiety. This suggests that the reduction in social 
behaviour observed in the social interaction test might reflect other distinct psychological 
domains that could be relevant to other psychopathological disorders such as depression 
(Tonissaar et al., 2008). At this regard, besides reduced social behaviour, two other 
features of the depressive-like phenotype in animals are behavioural despair/passive 
coping strategy and anhedonia. Both these behaviours were present after adolescent 
exposure to either synthetic or natural cannabinoids (Bambico et al., 2010; Realini et al., 
2011; Rubino et al., 2008), suggesting the presence of a depressive-like phenotype in 
adult animals after adolescent exposure to cannabinoids. This behavioural picture was 
associated with biochemical parameters related to depression, such as decreased CREB 
activation in the prefrontal cortex and hippocampus, increased CREB activation and 
dynorphin levels in the Nucleus accumbens, decreased neurogenesis in the dentate gyrus 
of the hippocampus. Interestingly, the depressive-like phenotype did not develop when 
the chronic cannabinoid administration was performed in adult animals (Bambico et al., 
2010; Realini et al., 2011), thus suggesting the existence of an age-dependent 
susceptibility of the brain to adverse effects of cannabinoids. 
 
PSYCHOTIC SYMPTOMS  
 
Experimental studies regarding long-lasting effects of adolescent cannabinoid exposure 
on psychosis-related behaviours in adult rodents are still scarce. It is impossible to model 
schizophrenia in its entirety in animals since this psychiatric disorder represents a 
complex condition with a very heterogeneous presentation of a variety of symptoms. 
Patients typically experience a combination of positive (e.g. hallucinations, delusions, 
thought disorganizations), negative (e.g. loss of motivation, affective blunting, alogia, 
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social withdrawal, and reduced hedonic capacity) and cognitive symptoms (e.g. deficits in 
attention, memory and executive functions). Since long-lasting effects of adolescent 
exposure to cannabinoids on the cognitive dimension and emotional reactivity have 
already been discussed above, this section will mainly discuss the positive symptoms. 
Since positive symptoms of schizophrenia such as auditory hallucinations and delusions 
are uniquely human, animal studies have focused on two main categories of behaviour: 
locomotor hyperactivity and disruption of prepulse inhibition (PPI). PPI measures 
sensorimotor gating that is the ability to filter out insignificant sensory information, a 
cognitive abnormality present in schizophrenia. Accordingly, loss of normal PPI is widely 
accepted as an endophenotype of schizophrenia with high translational validity, since it 
can be assessed in both animals and humans. Impairments in PPI in rats and mice were 
observed long after chronic treatment with the cannabinoid agonist WIN 55,212-2 in 
adolescence, suggesting the presence of disrupted sensorimotor gating (Wegener et al., 
2009; Schneider et al., 2003; Gleason et al., 2012). In contrast, other groups reported no 
alterations in this behaviour (Llorente-Berzal et al., 2011; Klug et al., 2013). The reason 
for this discrepancy is unclear: all groups used synthetic cannabinoid agonists, but the last 
three groups performed a longer treatment (15 or 21 days) with the same dose of agonist 
(CP55,940 or WIN 55,212-2), triggering a deep state of tolerance in animals. The former 
groups instead performed a shorter treatment (10 days) or used an irregular protocol of 
injections (none, one, or two daily injections for 25 days), and this could have led to a less 
profound tolerance. 
The concept of testing locomotor hyperactivity in animal models as a symptom of 
psychosis is based on the observation that enhanced dopaminergic activity in rodents 
leads to enhanced motor activity (Geyer, 2008). Accordingly, locomotor hyperactivity may 
have some face validity for certain components of the positive symptoms of 
schizophrenia, such as psychotic agitation (Van den Buuse, 2010). Rodent locomotor 
hyperactivity, either at baseline or induced by the treatment with psychoactive drugs, 
such as amphetamine or phencyclidine (PCP), has become commonly used as a 
behavioural tool to study the agitation that is typically present in human psychosis. 
Nonetheless, few papers have extensively investigated basal locomotor activity in adult 
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animals with pre-exposure to cannabinoids during adolescence, and they reported 
discrepant results. Indeed, no significant alterations in the open field recordings after CP-
55,940 (Biscaia et al., 2003 ) and THC (Rubino et al., 2008) were reported, but also the 
presence of locomotor hyperactivity after WIN 55,212-2 (Wegener et al., 2009), and 
reduced baseline locomotor activity after CP-55,940 (Klung et al., 2013). More recently, 
Zamberletti and colleagues (2014) monitored the effect of adolescent THC exposure on 
PCP-induced locomotor hyperactivity, and they found that THC increases the locomotor 
activating effect of acute PCP in adulthood. Similarly, PCP-induced stereotyped behavior 
was significantly enhanced in THC-treated rats. 
 
GATEWAY HYPOTHESIS  
 
An extremely important aspect emerging from the debate on Cannabis abuse among 
adolescents concerns the possibility that this behaviour could facilitate the subsequent 
use of other illicit substances. Known as the “gateway” hypothesis, this theory suggests 
that exposure to Cannabis increases the likelihood that an individual will use illicit drugs 
other than cannabis at some later point (Ellgren et al., 2008; Eggan et al., 2010; Lee et al., 
2013; Leweke et al., 2011; O’Shea et al., 2006, 2004; Quinn et al., 2008). According to this 
hypothesis, facilitated learning of cocaine self-administration was reported in adult 
female, but not male, rats pre-treated with cannabinoids in adolescence (Higuera-Matas 
et al., 2008). This could be associated with an up-regulation of dopamine transporter 
(DAT) in the caudate putamen (Higuera-Matas et al., 2010). Adolescent exposure to 
synthetic or natural cannabinoids did not alter dopaminergic or behavioural responses to 
amphetamine (Ellgren et al., 2004), even though an increased reinforcing effects of 
MDMA was observed in mice treated with cannabinoids during adolescence (Rodriguez-
Arias et al., 2010). This is in contrast with data obtained by Pistis and colleagues (2004); 
who showed that dopaminergic neurons were significantly less responsive to stimulation 
by WIN 55-212,2 (WIN) in animals pretreated for 3 days during adolescence or adulthood 
with WIN and allowed a 2-week washout (Pistis et al., 2004). However, in the group pre-
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treated in adolescence but not in adulthood, long-lasting cross-tolerance to morphine, 
cocaine and amphetamine developed, suggesting an enduring form of neuronal 
adaptation in dopaminergic neurons after sub-chronic cannabinoid intake at a young age. 
This, in turn, would have affected the subsequent responses to drugs of abuse. Regarding 
opioids, male rats showed a significant increase in the acquisition of both morphine and 
heroin self-administration, and this might be due to cannabinoid-induced alterations in 
the limbic mu opioid receptor system (Biscaia et al., 2008; Ellgren et al., 2008). Curiously, 
female rats seem to be unaffected by the same treatment (Biscaia et al., 2008). Even the 
different rat strain may affect the response: in Lewis rats, THC exposure did not affect 
heroin conditioned place preference (CPP), but potentiated reinstatement, while in Fisher 
344 rats THC exposure increased heroin CPP and made it resistant to extinction (Cadoni 
et al., 2015). These studies suggest the importance of sex and genetic background in 
determining the influence of THC exposure on opioid effects related to addiction.  
 
SEX-DIFFERENCES IN RESPONSE TO CANNABIS EXPOSURE 
 
Drug addiction is a widespread phenomenon affecting both men and women in different 
ways: sex-dependent differences have been frequently observed in the biological and 
behavioural effects of substances of abuse. Since drug abuse in female is a heavily 
increasing phenomenon, researchers are giving lot of importance to possible sex 
differences related to drug consumption, including Cannabis. Sex differences have been 
observed in the cannabinoid-induce effects related to cannabis abuse and dependence 
for example, men consume Cannabis in greater amounts and at higher rates than women 
do (Perez-Reyes et al., 1981) and, consequently, they appear to be more likely than 
females to become dependent on Cannabis (Wagner and Anthony, 2007; Fermer et al., 
2015). Males also exhibit higher circulating levels of THC (Jones et al., 2008), show larger 
cardiovascular and subjective effects than female smokers (Leatherdale et al., 2007), 
display more evident withdrawal symptoms (Crowley et al., 1998), are less likely to be 
Cannabis-only users and have a higher prevalence of panic disorder and personality 
disorder (Hasin et al., 2008). However, females tend to have shorter intervals between 
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the onset of use and regular consumption or development of dependence (Ridenour et 
al., 2006; Schepis et al., 2011). They also seem to experience negative consequences of 
drug use earlier than males, and to be more likely to suffer from an internalizing disorder, 
such as depressive and anxiety disorders (Kloos et al., 2009). One of the first study 
describing this correlation reported that daily Cannabis use was associated with a fivefold 
increase in anxiety and depression in young females, but not males (Patton et al., 2005). 
Accordingly, higher rates of comorbid mood and anxiety disorders in women have been 
recently observed in a large epidemiological study performed in the United States (Khan 
et al., 2013). 
Potential sex-differences have also been reported for Cannabis use and neurocognitive 
functioning (Crane et al, 2013): in fact, Cannabis use appears to be more consistently 
associated with poorer episodic memory performance in females and with poorer 
decision-making performance in males. Females Cannabis users present a larger 
prefrontal cortex volume compared to controls, whereas male users show a smaller one 
(Medina et al., 2009). It is worth noting that among users, larger prefrontal cortex total 
volume was associated with worse executive functioning. 
Animal models seem to confirm the existence of some sex-dependent responses to 
adolescent cannabinoid exposure, with females appearing more sensitive than males in 
the emotional sphere. On the contrary, literature suggests that adolescent exposure to 
cannabinoids induces long-term cognitive impairments specifically in recognition and 
spatial working memory, but these effects do not displays sex differences, since they are 
present in both male and female animals. Differences in behaviour are substantiated by 
differences at the cellular/molecular level, as female rats exhibit pronounced metabolism 
of THC to still active compound 11-OH-THC compared to their male conspecifics, 
particularly after repeated THC administration (Wiley and Burston, 2014). This fact, 
together with the observation that adolescent female rats possess more efficient CB1 
receptors (Rubino and Parolaro, 2011), suggests that they may be more vulnerable to THC 
effects. 
Accordingly, chronic THC exposure in adolescence induced more intense CB1 receptor 
desensitization in females, with more brain areas involved, despite similar down-
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regulation (Rubino et al., 2008; Burston et al., 2010). If confirmed also in humans, this 
would explain, at least in part, why females tend to have shorter intervals between the 
onset of use and the development of dependence (Ridenour et al., 2006; Schepis et al., 
2011; Khan et al., 2013; Hernandez-Avila et al., 2004). 
 
POSSIBLE MECHANISMS OF ADOLESCENT VULNERABILITY TO 
CANNABINOID EXPOSURE 
 
The first target of exogenous cannabinoids is the endocannabinoid system. Therefore, 
alterations in components of this system are expected after exposure to these 
compounds. According to this assumption, a profound CB1 receptor downregulation and 
desensitization has been observed after chronic THC treatment during adolescence in 
different cerebral areas (Rubino et al., 2015, 2008; Burston et al., 2010). This 
downregulation is less evident in male rats than in females, probably as a result of the 
different THC metabolism in the sexes (Wiley and Burston, 2014) and the alleged 
presence of more efficient receptors in adolescent female rats (Rubino et al., 2011). 
Moreover, in the PFC of THC-exposed female animals, the significant decrease of CB1 
receptor binding described immediately after the last THC injection and still present in 
adulthood was paralleled by a significant decrease of anandamide levels (Rubino et al., 
2015). Thus adolescent cannabinoid exposure alters the dynamic changes present in the 
endocannabinoid system during adolescence, likely affecting the neurodevelopmental 
processes in which this system might play a role.  
One of the most relevant events induced by chronic adolescent cannabinoid exposure in 
rodent models is the long-lasting negative impact on working memory and decision-
making. These high brain functions are refined during adolescence and are mainly 
dependent on the functional maturation of the PFC. According to recent literature, the 
endocannabinoid tone seems to play a fundamental role in some maturational processes 
within the glutamatergic system. Indeed, adolescent THC exposure induces a significant 
decrease in K+-evoked glutamate release in the adult hippocampus (Higuera-Matas et al., 
2012) as well as changes in the maturational fluctuations of NMDA and AMPA subunits in 
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the PFC of female animals, leading to larger amounts of GluN2B and GluA1 in adulthood 
(Rubino et al, 2015). Since NMDA receptors play a pivotal role in regulating the peri-
adolescent maturation of GABAergic networks in the PFC (Thomases et al., 2013), it might 
be assumed that even the GABAergic system could be affected by adolescent cannabinoid 
exposure. In line with this hypothesis, Zamberletti and colleagues (2014) demonstrated 
that chronic treatment with THC during adolescence in female rats resulted in reduced 
glutamic acid decarboxylase 67 (GAD67) and basal GABA levels in the PFC. These findings 
seem to indicate that adolescent cannabinoid exposure affects not only the 
endocannabinoid system but also the glutamatergic and GABAergic systems. These three 
systems are important in shaping cortical oscillations, a neural network activity in the 
neocortex (Uhlhaas et al., 2009) that is implicated in cognitive and sensory processing 
(Buzsáki et al., 2004; Wang et al., 2010). 
Furthermore, the adolescent brain is characterised by a high rate of synaptic pruning, 
especially in regions that govern higher cognitive function such as the PFC (Selemon, 
2013). Recent work suggests an important role of the endocannabinoid system in synaptic 
pruning. Thus, another event that might play a part in the brain alterations triggered by 
adolescent cannabinoid exposure should include changes in dendritic spines. Consistent 
with this assumption, male rats treated with a synthetic cannabinoid showed a significant 
reduction of dendritic spine density in the nucleus accumbens immediately after the 
treatment (Carvalho et al., 2016). Similarly, adolescent THC in male rats reduced spine 
density in the dentate gyrus of the hippocampus in adulthood, as well as dendrite length 
and number (Rubino et al., 2009). In adult female rats exposed to THC in adolescence, a 
significant decrease in the number of spines present on PFC pyramidal neurons was 
observed (Rubino et al., 2015).  
Recent evidence supports the involvement of epigenetic mechanisms in the development 
of psychiatric disorders (Renthal et al., 2009). For example, impairments in chromatin 
remodelling enzymes are increasingly being recognized as playing a crucial role in the 
development and maintenance of addictive disorders. It is, therefore, possible that 
Cannabis abuse during adolescence could impair the brain network functionality acting 
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through a mechanism involving epigenetic mechanisms, thus leading to long-term 
behavioral impairments.  
 
EPIGENETICS 
 
The term epigenetics is considered a neologism coined by Conrad Waddington in the early 
1940s, reflecting his attempt to integrate genetics with embryology. Indeed, Waddington 
used this term to explain how identical genotypes could produce different phenotypes 
during developmental processes through the epigenetic landscape metaphor 
(Waddington, 1957). From the conceptual point of view, this epigenetic landscape 
represents a series of choices facing an organism. Genes imposed the initial constraints 
and starting points, however, environmental and physiologic forces emerge during 
development. These forces then operate in coordination with genes, pushing the 
organism into typically deeper canals, the so-called attractors of the landscape, resulting 
in the organism's phenotype. Through this process of canalization, individual organisms 
that might have identical genotypes could develop radically different phenotypes 
(Waddington, 1957). The recent use of this concept focuses on the molecular 
modifications of DNA and chromatin that are thought to change gene expression allowing 
transcriptional regulation of genes without altering DNA sequence (Jaenisch and Bird, 
2003).  
Chromatin is made up by a fundamental unit named nucleosome, which is composed of 
147 bp of DNA wrapped around an octamer of core histone proteins (two copies each of 
H2A, H2B, H3, and H4). Nucleosomes are connected one to the other by linker DNA, with 
a length ranges between 20–90 bp, and by histone H1 that condenses nucleosomes into 
higher order structures (Jenuwein and Allis, 2001; Gardner et al., 2011). Since DNA is 
closely associated with histones and often embedded within chromatin supercoils, there 
are cellular mechanisms that modify and reshape the chromatin structure to allow the 
coordinated expression of specific transcriptional programs and the silencing of others. 
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Among the epigenetic mechanisms, we are going to mention methylation of DNA and 
histone modifications. (Fig.4) 
 
DNA METHYLATION  
 
DNA methylation (Fig.4)  is an enzymatic process by which methyl groups are added to 
the DNA at the level of cytosine in the 5 position, resulting in the formation of a methyl 
group protruding into the major groove of DNA (Newell-Price et al., 2000). In mammals, 
these 5-methylcytosine are mainly present at 5'-CpG-3'palindromic sequences and do not 
interfere with the normal hydrogen bonds with the complementary base guanine. These 
CpG dinucleotide sequences are randomly distributed in the genome, presenting the 
higher concentration at the level of the so-called CpG islands. CpG islands coincide with 
50-60% of human promoter regions of genes and are typically methylated to a much 
lesser extent than the CpG dinucleotides located outside the islands (Wang and Leung, 
2004). Methylation of CpG dinucleotides in gene promoter regions is generally associated 
to transcriptional repression because of its ability to prevent the binding of transcription 
factors to their target sequences. About 3% of all cytosine in the human genome is 
methylated (Nafee et al., 2008), and the correct methylation of these bases is essential 
for normal development. This is associated with a number of key processes including 
cellular differentiation, genetic imprinting, repeated elements suppression, and X-
chromosome inactivation (Bird, 2008). DNA methylation is catalysed by DNA methyl-
transferases (DNMTs), which transfer a methyl group from S-adenosyl methionine (SAM) 
to cytosine residues of CpG dinucleotides. DNMTs family of enzymes include DNMT1, 
DNMT2, DNMT3a and DNMT3b (Weber and Schubeler, 2007). These enzymes play 
different roles, equally crucial: DNMT1 maintains the methylation pattern during DNA 
replication, DNMT3a and DNMT3b seem to catalyse the de novo methylation of the 
previously unmethylated DNA double filament (Newell-Price et al., 2000; Kim et al., 2009), 
and DNMT2, on the other hand, is capable of methylating RNA (Goll et al., 2006). 
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HISTONE MODIFICATIONS  
 
Histone modifications (Fig.4) represent an epigenetic mechanism that acts on the degree 
of chromatin condensation. Histones are basic proteins (H1, H2A, H2B, H3 and H4) that 
form the histone octamer core around which DNA is wrapped to form the nucleosome, 
the fundamental unit of chromatin.  
The histone N-terminal tail may undergo a variety of post-translational changes such as 
acetylation, methylation, phosphorylation, ADP-ribosylation and ubiquitination. In 
particular, some of these modifications (e.g. H3K9me and H3K27me) make the chromatin 
more compact (heterochromatin), excluding therefore the transcriptional machinery. 
Conversely, other modifications (e.g. H3K4me; H3K9ac) relax chromatin structure 
(euchromatin) so that the nucleosome assumes a transcriptionally active structure 
exposing promoter regions for transcription factors and allowing gene transcription. This 
suggests that histone modifications influence gene expression by means of chromatin 
remodelling and recruitment of transcription factors, which can activate or repress gene 
transcription (Berger, 2007; Borrelli et al., 2008; Jenuwein and Allis, 2001). 
 
HISTONE ACETYLATION  
 
Histone acetylation is a dynamic process controlled by specific enzymes that add or 
remove acetyl groups. Indeed, different classes of histone acetyl-transferases (HATs) are 
able to add acetyl groups to lysine residues of histone tails. This modification reduces 
electrostatic interaction between DNA and histone proteins, relaxing the chromatin 
structure and enabling transcription factor to bind promoter regions of specific genes 
(Kouzarides, 2007). Histone acetylation is therefore associated with transcriptional 
activation; on the contrary, its lack is associated with gene repression. HATs use acetyl-
CoA as a substrate for the reaction and they can add acetyl group even to non-histone 
proteins such as transcription factors (Doi et al., 2006; Kawasaki et al., 2000). In contrast, 
histone deacetylases (HDACs) remove acetyl groups from the histones and they are 
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divided into four classes. Class I HDACs (HDAC 1, 2, 3 and 8) are ubiquitously expressed 
and probably mediate most of the deacetylase activity in the cells. Class II HDACs (HDACs 
4, 5, 7, 9 and 10) are only expressed in specific tissues such as heart and brain (Chawla et 
al., 2003). Lastly, class III HDACs (sirtuins) are different from other HDACs and they have 
been implicated in the regulation of life expectancy and metabolism (Haigis and 
Guarente, 2006).  
 
HISTONE METHYLATION  
 
Histone methylation can be associated with both transcriptional activation and 
repression. This depends on which amino acidic residue is methylated and on its own 
degree of methylation. Histone methyl-transferases (HMTs) are enzymes that catalyse 
the transfer of one, two, or even three methyl groups to lysine and arginine residues of 
histone H3 and H4, by using S-adenosylmethionine as a substrate. In contrast to 
acetylation, methylation does not alter the target residue charge. However, methylation 
can widely modify the steric profile and the potential molecular interactions by adding 
mono-, di- or tri-methyl groups. This modification makes each site capable of recruiting 
specific co-regulators and exerting different effects on transcriptional activity. For 
example, H3K4 trimethylation is associated with gene activation, while H3K9 or H3K27 
trimethylation is repressive (Maze et al., 2010). 
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Figure.4 Epigenetic mechanisms: methylation of DNA and histone modifications 
 
 
EPIGENETIC MECHANISMS IN PSYCHIATRIC DISORDERS 
 
Epigenetic mechanisms control normal brain function, and histone modifications have 
been related to neural plasticity and multiple forms of behavioural memory (Levenson 
and Sweatt, 2005; Borrelli et al., 2008; Dulac, 2010; Nestler, 2011). Through the 
investigation of epigenetic markers, it is possible to understand whether a gene is 
transcribed or silenced during a particular stage of a brain disease. Indeed, epigenetics 
can provide bases for determining different transcriptional states, enabling us to identify 
genes and proteins involved in neuropsychiatric disorders. Moreover, the study of 
epigenetic mechanisms could provide a valid theory that links genetic factors to different 
environmental factors, helping us to understand the etiology of the various 
neuropsychiatric pathologies.  
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Starting from this assumption, recent studies have reported that alterations in some 
epigenetic markers are present in suicide victims suffering from depression, suggesting 
involvement of epigenetic mechanisms in this pathology (Autry and Monteggia, 2009). In 
particular, histone acetylation seems to play an important role in depression. Indeed, 
mice subjected to chronic social defeat stress (an animal model for depression) show a 
transient reduction in acetylated histone H3 at lysine 14 (H3K14Ac) in the Nucleus 
Accumbens (NAc). The NAc is a brain area that is deeply important for processing stimuli 
related to reward (Wise, 1987; Koob, 1996; Carelli, 2002). Clinical depression often 
includes anhedonic, motivational, and arousal deficits, suggesting that the NAc may 
present an important role in mediating these symptoms (Nestler and Carlezon, 2006). 
Local infusion of MS275 (selective inhibitor of class I HDAC) has an antidepressant effect 
and, conversely, over-expression of HDAC2 has a depressive effect, suggesting the 
importance of these enzymes in the development of depression. Furthermore, the 
chronic stress paradigm alters acetylation levels even in the Hippocampus, a brain region 
highly sensitive to the effects of stress and implicated in regulating stress responses, as 
well as in the Amygdala, an area involved in integrating higher brain functions such as 
emotions and cognitive memory (Covington HE et al., 2011). Chronic social defeat stress 
decreases di-methylated histone H3 at lysine 9 levels (H3K9me2) in the Nucleus 
accumbens, resulting in transcriptional repression. This alteration is related to G9a down-
regulation, a histone methyl-transferase responsible for this modification. More studies 
are necessary to fully understand the role played by these histone modifications in 
depression.  
Considering schizophrenia (SZ), a mental disorder characterized by psychotic symptoms 
such as delusions and hallucinations, experimental evidence suggests the involvement of 
epigenetics in its pathogenesis. Indeed, previous research reported the presence of a 
hyper-methylated state of the promoter of genes encoding for glutamate decarboxylase 
67 (GAD67), an enzyme that catalyses the decarboxylation of glutamate to GABA and 
CO2, and reelin, an extracellular matrix glycoprotein involved in neuronal migration and 
in schizophrenia (Akbarian et al., 2009; Huang et al., 2007; Chen et al., 2002; Costa et al., 
2002). This suggests that hyper-methylated DNA in the promoter region of the coding 
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gene for reelin may be responsible for the reduced expression of this protein in SZ 
patients. Furthermore, it has recently been demonstrated that the administration of 
HDAC inhibitors is able to reactivate reelin and GAD67 transcription to a dose comparable 
to that of DNMT inhibitors (Kundakovic et al., 2009). These findings therefore suggest the 
possibility of using epigenetic drugs, either individually or in combination, as new 
potential therapies to reduce protein deficiencies and the clinical symptoms associated 
with SZ. 
Epigenetic mechanisms have also been described after exposure to abused drugs. Data 
reported in literature show that after acute cocaine administration a rapid increase in 
acetylation of histone H4 (a marker associated with transcriptional activation) occurs in 
specific genes known to be involved in behaviours related to cocaine intake (Kumar et al., 
2005). Moreover, a global increase of H3K9me3 (a marker associated with transcriptional 
repression) is observed (Kumar et al., 2005). This could be a compensatory mechanism 
carried out by the body to counterbalance the negative effects of histone hyper-
acetylation induced by cocaine exposure. According to this data, recent studies 
performed in our laboratory have shown that adolescent THC exposure induces 
significant epigenetic alterations in the Prefrontal cortex of female rats. Indeed, two 
hours after the last THC injection, a significant increase in H3K9me3 levels is observed. 
This alteration increases its intensity 24 hours later and is paralleled by a significant raise 
of H3K9me2 and H3K14ac levels. Finally, 48 hours after the end of the treatment, the 
observed alterations are returned to control levels, meanwhile K9 acetylation levels 
significantly increase. Such alterations are associated with significant changes in the 
transcription of genes involved in synaptic plasticity (Prini et al., 2018). A previuos study 
has found persistent changes in repressive H3K9me2 and H3K9me3 at proenkephalin 
opioid neuropeptide (Penk) locus in the NAc of adult rats following adolescent THC 
exposure in line with enduring upregulation of Penk mRNA levels (Tomasiewicz HC et al., 
2012). 
Overall, these data suggest that epigenetic modifications are strongly related to the 
etiopathogenesis of psychiatric disorders such as depression, schizophrenia and drug 
abuse. Consistently with this hypothesis, studies performed over the last years have 
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demonstrated that histone modifications represent an important epigenetic mechanism 
for the translation of environmental stimuli -including drug abuse- into changes of gene 
expression (Feng and Nestler, 2013; Schmidt et al., 2013).  
It is therefore possible that Cannabis abuse during adolescence could impair the brain 
network functionality acting through a mechanism involving histone modifications, thus 
leading to long-term behavioural impairments. Nevertheless, further studies are needed 
in order to understand how changes in these mechanisms may contribute to brain and 
behaviour alteration induced by adolescent THC exposure. 
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Despite the accumulation of evidence of a possible relationship between adolescent 
Cannabis abuse and the later development of psychiatric disorders, Cannabis remains the 
most common illegal drug used by adolescents. Consistently with the epidemiological 
data, we have previously demonstrated that THC administration to adolescent female 
rats induces the onset of a depressive/psychotic-like phenotype. Interestingly, only 
adolescent THC exposure, but not the adult one, led to this complex phenotype, 
suggesting that adolescence may represent a vulnerable period for the adverse effect of 
THC. However, the neurobiology of this vulnerability is not completely understood and 
thus needs further investigation. 
Several papers support the involvement of histone modifications in the pathogenesis of 
psychiatric illnesses. In line with these data, we demonstrated that THC alters histone 
modifications in the Prefrontal cortex (PFC) of female rats. Alterations in histone 
modifications were paralleled by changes in the expression of a subset of plasticity genes 
relevant for the development of cognitive deficits present at adulthood. Interestingly, 
alterations in both histone modifications and gene expression were more intense and 
widespread following adolescent THC treatment compared to adult. This differential 
effect clearly indicates an age-dependency in THC-induced molecular alterations, at least 
in the PFC, highlighting new possible molecular mechanisms underlying adolescent 
susceptibility to develop substance-induced psychopathologies. 
On these bases, the first aim of this thesis is to extend our knowledge on the impact of 
THC exposure on histone modifications occurring in other brain areas that, along with the 
PFC, are important for the different aspects of the phenotype described previously in 
female animals.  
To this aim, adolescent (PND 35-45) and adult (PND 75-85) female Sprague-Dawley rats 
will be treated twice a day with increasing intraperitoneal (ip) doses of THC: 2.5 mg/kg, 5 
mg/kg, 10 mg/kg or its vehicle. Two, 24 and 48 hours after the end of the treatment, the 
animals will be sacrificed in order to collect the brain areas of interest: Hippocampus 
(Hippo), Nucleus Accumbens (NAc), and Amygdala (Amy). These brain areas undergo 
dramatic changes during adolescence and are mainly affected by Cannabis consumption. 
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Western blot assays will be performed in order to evaluate some of the histone 
modifications that are involved in the development of psychiatric disorders. Specifically, 
we will investigate histone modifications associated with both transcriptional repression 
(H3K9 di- and tri-methylation, H3K27 trimethylation) and activation (H3K9 and H3K14 
acetylation). Moreover, to investigate the existence of age-specificity of THC effects, the 
study will be performed after both adolescent and adult exposure. By means of this 
approach, we will be able to complete the picture of the possible histone modifications 
induced by THC exposure during adolescence and adulthood in female rats. 
Recent literature reported that Cannabis consumption is able to impair behaviour in a 
sex-dependent manner. Indeed, women mainly develop depression/anxiety, whereas 
men mainly suffer from attention-deficit hyperactivity and anti-social personality 
disorders. Accordingly, our research group was able to reproduce age- and sex-dependent 
effect of THC in animal models. Specifically, chronic THC exposure during adolescence 
causes long-term disturbances of cognitive performances and emotional reactivity in 
adult female rats. In contrast, adolescent male rats exposed to THC developed a 
psychotic-like phenotype at adulthood, characterized by anhedonia, cognitive deficits and 
phencyclidine sensitization.  
Based on these results, the second aim of this thesis is to extend our knowledge on the 
impact of adolescent THC exposure on histone modifications occurring in different brain 
areas of male rats.  
To this aim, adolescent (PND 35-45) male Sprague-Dawley rats will be treated with the 
same protocol previously described. Two, 24 and 48 hours after the end of the treatment, 
the animals will be sacrificed in order to collect the brain areas of interest: Prefrontal 
cortex (PFC), Hippocampus (Hippo), and Nucleus Accumbens (NAc). Western blot assays 
and histone markers evaluation will be performed with the same protocol used for 
females. 
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Data obtained will contribute to better understand part of the molecular events that 
make the adolescent brain more sensitive to the adverse effects of Cannabis and thus 
contribute to the development of psychiatric disorders. 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
MATERIALS AND METHODS 
 
 
 
 
 
 
 
35 
 
ANIMALS  
The experiments have been conducted on adolescent female and male (PND 35-45) and 
adult female (PND 75-85) Sprague-Dawley rats (Charles River, Calco, Italy) with an average 
weight of 90-110 grams (PND 28) and 200-220 grams (PND 70) at the beginning of the 
treatment. The animals were fed with pellet diet and ad libitum water, and they were 
housed in groups of five animals per cage under standard conditions (22±2°C, 60±5% 
humidity, twelve hours of artificial daytime lighting). All the experiments were carried out 
in strict accordance with the guidelines for care and use of experimental animals in the 
European Communities Council directive (2010/63/UE L 276 20/10/2010) and approved 
by the Ethical Committee for Animal Research at the University of Insubria and by the 
Italian Ministry of Health (Aut. N.302/2015-PR). All efforts have been made to reduce the 
suffering and the number of animals utilized. 
 
DRUGS  
The following drug was used to carry out the experiments of this thesis: THC. THC was 
generously offered by GW Pharmaceuticals (Salisbury, UK). THC was dissolved in ethanol, 
Kolliphor and saline (1:1:18). 
 
TREATMENTS  
After a 7-day relapse period, the rats were randomized into two experimental groups: the 
first group was treated with the natural cannabinoid agonist Δ9-THC, and the second one 
with its vehicle. For adolescent animals, chronic treatment began 35 days after birth (PND 
35) and ended 10 days after (PND 45). Rats were treated twice a day with increasing 
intraperitoneal (ip) doses of THC: 2.5 mg/kg (PND 35-37), 5 mg/kg (PND 38-41), 10 mg/kg 
(PND 42-45) or with its respective vehicle. The same scheme of treatment was performed 
on adult animals starting 75 days after birth (PND 75). According to the transformation in 
human equivalent dose proposed by FDA and the average content of THC in a joint, this 
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protocol mimics a heavy Cannabis abuse. Indeed, the first dose approximately 
corresponds to one joint containing 7% of THC, the second one to two joints, and the 
higher one to four joints. Currently, existing strains of Cannabis have reached a content 
of THC up to 14%. In this case, our treatment would mimic the consumption of half a joint 
(first dose), one joint (second dose) and two joints (third dose). 
 
 
 
 
 
 
 
 
 
Figure 5. Adolescent (A) and adult (B) THC treatment schedule. 
 
BIOCHEMICAL ASSAYS  
Animals were sacrificed and their brains collected at 2, 24 and 48 hours after the last THC 
administration. For biochemical assays, the brains were quickly removed and brain areas 
of interest (Hippo, NAc, and Amy) were obtained by regional dissection on ice through an 
aluminium block by following the Heffner method (Rodent Brain Matrix, ASI instrument, 
Warren, MI USA) which allows to obtain brain sections of 1 mm thick. In the section of 
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interest, identified with the aid of Paxinos and Watson (1986) atlas, the area was collected 
from both the right and the left hemispheres. The obtained cerebral areas were 
immediately frozen in liquid nitrogen and stored at -80°C until processing. 
 
HISTONE EXTRACTION  
The brain areas of interest were homogenized by using a glass/Teflon potter in ice-cold 
buffer (50 mM Tris-HCl pH 7.5, 1 mM EDTA, 5 mM MgCl2, NaCl 50 mM, 5% Glycerol, 1% 
Triton, 2 mM DTT, 2 mM PMSF, 2µg/ml Aprotinin; 2µg/ml Leupeptin, 50 mM NaF) and 
centrifuged at 13.000 rpm at 4 °C for 5 min. The pellet was resuspended in nuclear lysis 
buffer (Hepes 20 mM pH 8, MgCl2 1.5 mM, NaCl 420 mM, DTT 2 mM, PMSF 2 mM, EDTA 
0.2 mM, NaF 50 mM, 25% Glycerol, aprotinin 10 μg/ml, and leupeptin 10 μg/ml) and 
incubated on ice for 30 min with mild agitation. The samples were centrifuged at 13000 
rpm for 10 minutes at 4°C. The pellet was resuspended in 0.2 M HCl, incubated on ice for 
30 minutes with mild agitation and then overnight at 4°C to acid extract histones. The 
samples were then centrifuged at 10000 rpm for 10 minutes at 4°C. The supernatant 
containing the histone proteins was mixed with 6 volumes of cold acetone and incubated 
at -20°C overnight to precipitate histones. The following day, the samples were 
centrifuged at 4000 rpm at 4°C for 10 minutes and the pellets were resuspended in RIPA 
Buffer (Tris-HCl 50 mM pH 7.5, EDTA 2 mM, NaCl 150 mM, Triton 1%, PMSF 2 mM, 
Aprotinin 5µg/ml; Leupeptin 5µg/ml). The protein concentrations were determined 
according to the Micro-BCA assay kit (Pierce, Rockford, IL). 
 
PROTEIN ASSAY THROUGH BCA METHOD 
The assay is a detergent-compatible formulation based on bicinchoninic acid (BCA) used 
for colorimetric determination and quantification of total proteins. This method 
combines the copper reduction (Cu2+ → Cu1+) mediated by the protein into an alkaline 
medium (biuret reaction) with highly sensitive and selective colorimetric determination 
of Cu+1 cation using a single BCA containing reagent. The colorimetric reaction is due to 
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the chelation of two BCA molecules with a copper ion. This water-soluble complex 
exhibits a strong absorbance at 570nm, which is linear with the increase in protein 
concentration within a broad spectrum ranging from 20 μg/ml to 2000 μg/ml. In this 
assay, a protein set with known concentration was prepared by diluting the stock of 
standard BSA (Bovine Serum Albumin, 2 mg/ml; Pierce). The concentrations used to dose 
the samples should fall into the standard protein set, appropriately chosen in relation to 
the concentrations of the samples themselves. The appropriate concentrations of each 
standard and samples that need to be dosed were placed in wells of a special plate. The 
"Working Reagent" solution was prepared by mixing 50 parts of reagent A (Sodium 
carbonate, Sodium Bicarbonate, reagent for BSA detection and Sodium Tartrate in 0.2 N 
NaOH) with 1 part of reagent B (25 Copper sulphate at 4%). At this point, 200 μl of the 
Working Reagent solution was added to each well of the plate, which was finally 
incubated for 30 minutes at 37 °C. The absorbance of each sample was then measured at 
570 nm. The linear equation from which inferring the protein concentrations of the 
individual samples expressed in micrograms of protein/microliter (μg/μl) of homogenated 
tissue was calculated by a linear regression analysis performed on the computer (Prism, 
Graph Pad). 
 
SDS-PAGE 
The SDS-PAGE technique is definitely the most commonly used to analyze complex 
protein mixtures. Proteins react with sodium dodecyl sulphate (SDS), an anionic detergent 
that coats proteins forming negatively charged complexes. The amount of SDS bound to 
a protein, and hence the total charge of the complex, is proportional to its molecular 
mass. SDS binds to polypeptides in a constant weight ratio of 1.4g SDS/g of polypeptide. 
The proteins are denatured and solubilized by binding to the SDS. At this point, the 
complex assumes a helicoidal form depending on the molecular weight of the protein. 
Thus, proteins at the specific isoelectric point, either acidic or basic, form negatively 
charged complexes that can be separated according to their mass differences by means 
of electrophoresis and by passing through a sieve composed by a polyacrylamide gel 
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matrix. The widespread use of this technique is due to the excellent resolution power, 
linked to the use of a discontinuous system that employs two gels, a "stacking gel" and a 
"running gel", each one having a different density. This system uses the principle of 
“isotachophoresis ", which effectively concentrates large volumetric samples into very 
small bands, thus obtaining a better separation of the different molecular species present 
in the mixture. The system is set up by superimposing the "stacking gel" to the “running 
gel”, which present different pH and polyacrylamide concentrations. Samples are loaded 
into wells that are located at the level of the "stacking gel", and when an electric field is 
applied, negative charge ions migrate to the anode (positive pole). However, protein-SDS 
complexes have intermediate mobility between chlorine ions (present throughout the 
system) and glycinate ions (present in the Running Buffer) at the pH present in the 
"stacking gel" (pH 6.8), whereas chlorine ions have a greater mobility. Immediately, larger 
ions concentrate in tight areas in the "stacking gel", but here they are not effectively 
separated. When complexes reach the "running gel", their respective mobility varies 
according to the different prevailing pH (pH 8.8) and the glycinate-formed front reaches 
the bands of protein-SDS complexes. This allows the separation of proteins by their mass 
in a uniformly buffered electric field. The system used and described by Laemmli uses the 
following reagents: 
1) Acrylamide / bisacrylamide solution (ratio 37:1); 
2) Blends of running gel at 14%: Tris buffer 8.8, 1.5 M (mother), consisting of Trizma 
Base, SDS and H2Od; 
3) Blends of stacking gel at 4.5%: Tris Buffer 125mM (Mother 0.5M pH 6.8), Acrylamide 
4.5% (Mother 40%), Ammonium Persulfate 10%, Temed; 
4) SDS-PAGE 5X buffer: Glycine, 0.96M, Tris base 0.125 M SDS 0.5%. 
Both Temed and ammonium persulfate reagents, lastly added to the blends, trigger the 
polymerization of the polyacrylamide solution. The "stacking gel" is superimposed on the 
"running gel" when the latter is polymerized. During the polymerization, a suitable comb 
that allows to obtain wells with a capacity of about 20-25μl is inserted in the stacking gel. 
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Once polymerized, the gels are placed into the electrophoretic chamber and the combs 
removed in order to form the wells in which the samples are loaded.  Both the samples 
and the appropriate reference standards (protein markers), consisting of a known 
molecular weight protein mixture, are loaded into the wells. The samples run into the gel 
by applying a constant current of 20 mA/gel. A protein amount corresponding to 15 γ for 
histone samples and 30 γ for nuclear extracts was loaded in each well of the gel. The 
samples were appropriately prepared in Laemmli buffer 5X (Tris HCl 1M pH 6.8, SDS 10%, 
Bromophenol blue 0.05%, glycerol 50%, DTT 5%) and diluted with H2Od to obtain a 
concentration of Laemmli Buffer 1X. The so prepared samples were boiled for 3 minutes 
(10 minutes in the case of histone proteins), to ensure complete protein denaturation 
and, eventually, they were placed in ice ready to be loaded. 
 
WESTERN BLOT 
Western blot assay is based on the ability to transfer proteins, previously separated by 
gel electrophoresis, onto a suitable membrane by using a device called "semi-dry cell" 
(Trans-blot, Biorad) and by applying a constant voltage for about 15 minutes. On the 
surface of the device representing the anode, four sheets of Whatmann 3MM filter paper, 
previously soaked into glycine buffer (Trizma base 25mM, glycine 150mM, 10% methanol, 
pH 8.3), were placed. After being activated into the glycine buffer for at least 30 minutes, 
PVDF membranes were located onto the four sheets of filter paper along with the gel in 
which proteins had migrated according their molecular weight. The sandwich was 
completed by adding four other Whatmann filters. The system was then hermetically 
closed by placing the lid of the device representing the cathode on this pile. In this way, 
the “semi-dry” transfer begins. After the transfer, PVDF membranes are incubated for 
about two hours in a "blocking solution" (lean milk in powder Regilait 5% dissolved into 
TBS-Tween 20: Trizma Base 20mM, NaCl 150mM, Tween 20 0.1%, pH 7.5), in order to 
saturate the nonspecific binding sites. After this process, we proceeded with an overnight 
incubation at 4°C with the primary antibody. The primary antibodies that were used are 
the following: (I) monoclonal anti-Histone H3 di methyl K9 (1:1000, AbCam), (II) polyclonal 
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anti-Histone H3 tri methyl K9 (1:1000, AbCam), (III) polyclonal anti-Histone H3 tri methyl 
K27 (1:1000; Merck Millipore, Darmstadt, Germania), (IV) polyclonal anti-Histone H3 
acetyl K9 (1:1000; Merck Millipore), monoclonal anti-Histone H3 acetyl K14 (1:1000; 
Merck Millipore), (V) polyclonal anti-Histone H3 (1:5000; AbCam). The membranes went 
through 5 five-minute-lasting washings in TBS-Tween 20, and 1 two-minute-lasting 
washing in blocking solution. Bound antibodies were detected with horseradish 
peroxidase linked to anti-rabbit or anti-mouse antibody (1:3000/5000; Chemicon 
International, Temecula, CA). We then proceeded with 5 other 5-minute washings in TBS-
Tween 20 and a 2-minute washing in TBS 1X. Finally, membrane were removed from the 
last washing and processed for development through electrochemiluminescence (ECL) 
method. 
 
DEVELOPMENT THROUGH ECL METHOD 
Electrochemiluminescence is a method that allows to detect immobilized proteins 
present on PVDF membranes and conjugated, either directly or indirectly, with HRP 
antibodies. Such protein detection system consists of a chemo-luminescence reaction: 
the HRP, linked to the secondary antibody, oxidizes a peracid salt present in the solutions 
for the ECL, causing HRP oxidation and catalyzing the oxidation of luminol. This, in turn, 
causes the passage of the electrons to an excited state followed by a decay to baseline 
levels, which determines the emission of light at a wavelength of 428 nm. G:BOX iChemi-
XT16 Imaging System (Syngene, Cambridge, UK) was used for image acquisition. The 
relevant immunoreactive bands were quantified through scanning densitometry using 
ImageJ software. Expression of the proteins was normalized to total histone H3 for 
histone samples. This technique allows to point out whether the protein differences 
obtained are real or due to experimental errors; indeed, after performing the stripping, 
the PVDF membranes are incubated with a primary antibody recognizing total histone H3. 
This protein is encoded by a "housekeeping gene" that allows to quantify the total protein 
concentration of the loaded sample. 
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STRIPPING 
By means of this method, it is possible to remove the protein-antibody binding and re-
use the same membrane with a new antibody. The procedure presents the following 
steps: 
• Washing of the membrane with the stripping solution maintained at 37°C for 15  
        minutes; 
• 3 five-minute-lasting washings in TBS Tween; 
• Possibly, repeat the procedure a second time; 
• Incubation of the membrane in blocking solution for about 2/3 hours; 
• Incubation with primary antibody. 
 
STATISTICAL ANALYSIS 
Statistical analysis is performed by using Prism 4.0 version (Graph  Pad  software,  inc.,  
San Diego,  CA,  USA). Data are presented as mean ± SEM of at least five animals per 
group. Statistical analyses were performed by using Student’s t-test in order to compare 
two groups of data. 
Data on THC- treated animals were further analyzed by two-way MANOVA (using Wilks’s 
Λ statistics). In particular, fold change values were log transformed and then analyzed by 
two-way MANOVA, one for each time point (2, 24, 48 hours), considering the brain area 
(hippocampus, nucleus accumbens and amygdala) and the status (adolescent and adult) 
as independent variables. Results were confirmed by two-way ANOVA (one for each time 
point/histone modification pair), followed by the Tukey post-hoc test with the Benjamini-
Hochberg correction of p values, in order to highlight significant contrasts. 
 
 
 
 
 
 
 
 
 
 
RESULTS 
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ANALYSIS OF THC-INDUCED HISTONE MODIFICATIONS IN 
DIFFERENT BRAIN AREAS OF FEMALE RATS 
 
We and others have demonstrated that adolescent exposure to THC, or to synthetic 
cannabinoids, induces sex-dependent brain and behavioural alterations at adulthood 
(Rubino et al., 2008, 2009, 2015; Realini et al., 2011; Zamberletti et al., 2014, 2015, 2016; 
Higuera-Matas et al., 2008, 2012, Biscaia et al., 2003; Schneider and Koch, 2003). In 
female rats, the phenotype was more complex, as both depressive-like and psychotic-like 
signs were present, thus, firstly, we decided to further our understanding of adolescent 
cannabis exposure in females. We hypothesized that cannabis abuse during adolescence 
could impair the brain network functionality acting through a mechanism involving 
histone modifications, thus leading to long-term behavioural impairments. Accordingly, 
we demonstrated in the PFC that THC alters histone modifications, mainly methylation of 
H3K9, and the expression of a subset of plasticity genes relevant for the development of 
cognitive deficits present in the adult phenotype (Prini et al., 2018). Interestingly, the 
alterations induced by THC exposure were age-specific. Indeed, not only the behavioural 
phenotype developed after adolescent, and not adult, exposure (Realini et al., 2011), but 
also changes in both histone modifications and gene expression were more widespread 
and intense after adolescent treatment (Prini et al., 2018]. 
On these bases, the first aim of this thesis was to extend our knowledge of the impact of 
THC exposure on histone modifications occurring in other brain areas that, together with 
the PFC, are important for the different aspects of the depressive/psychotic-like 
phenotype described in these animals (Rubino et al., 2008, 2009, 2015; Realini et al., 
2011; Zamberletti et al., 2015).  
To this aim, we investigated histone modifications associated with both transcriptional 
repression (H3K9 di- and tri-methylation, H3K27 trimethylation) and activation (H3K9 and 
H3K14 acetylation), since they have already been reported to be modulated by drug 
treatment (Peña et al., 2014). These analyses were performed 2, 24, and 48 h after the 
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last THC injection in the Hippocampus (Hippo), Nucleus accumbens (NAc), and Amygdala 
(Amy), brain areas which undergo dramatic changes during adolescence and which are 
mainly affected by drug consumption (Koob and Vilkow, 2016; Sharma and Morrow, 
2016). To investigate the existence of age-specificity of THC effects, the study was 
performed after both adolescent and adult exposure, which consisted of increasing doses 
of THC for 11 days, as reported in Figure 5.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Adolescent (A) and adult (B) THC treatment schedule. 
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EFFECT OF ADOLESCENT THC EXPOSURE ON HISTONE 
MODIFICATIONS 
In the Hippocampus of female rats (Fig.6), H3K14ac levels were significantly reduced 
(34%) 2 hours after the end of THC treatment. On the contrary, a significant increase 
(57%) in H3K14ac levels was observed 24 hours later. At this same interval of time, an 
enhancement of H3K9me2 (36%) and H3K9me3 (30%) was also observed. Finally, 48 
hours after the end of the treatment, all these alterations returned to control values. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Effect of adolescent THC exposure on histone modifications occurring in the hippocampus of female rats, 
2, 24 and 48 hours after the last THC injection. Data are expressed as mean ± SEM of at least eight animals for each 
experimental group. *p<0.05 versus controls (Student's t-test analysis). 
 
Concerning the Nucleus Accumbens (Fig. 7), H3K9me3 was significantly increased (50%) 
2 hours after the end of THC treatment. This enhancement was maintained (43%) 24 
hours later, and it was paralleled by a significant increase in H3K9me2 (42%) and H3K14ac 
(26%) levels. On the contrary, at the later time-point studied (48h), H3K9me3 levels, as 
well as H3K9me2 and H3K14ac levels were significantly reduced (16%, 23%, and 28%, 
respectively). 
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Figure 7. Effect of adolescent THC exposure on histone modifications occurring in the Nucleus Accumbens of female 
rats, 2, 24 and 48 hours after the last THC injection. Data are expressed as mean ± SEM of at least eight animals for 
each experimental group. *p<0.05 versus controls (Student’s t-test analysis) 
 
Regarding the amygdala (Fig.8), adolescent THC administration induced a significant 
increase in H3K9me2 (33%) levels 2 hours after the end of the treatment. Twenty-four 
hours later, while this alteration returned to control values, H3K9me3 levels were 
significantly enhanced (33%). Finally, 48 hours after the last THC administration, no 
significant changes were observe 
 
 
 
 
 
 
 
 
 
Figure 8. Effect of adolescent THC exposure on histone modifications occurring in the amygdala of female rats, 2, 24 
and 48 hours after the last THC injection. Data are expressed as mean ± SEM of at least eight animals for each 
experimental group. *p<0.05,**p<0.01 versus controls (Student’s t-test analysis). 
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As a whole, these data suggest that THC effect on histone modifications is strictly 
dependent on the brain region under consideration. 
 
EFFECT OF ADULT THC EXPOSURE ON HISTONE MODIFICATIONS 
Since the development of the depressive/psychotic-like phenotype in female rats is 
restricted to adolescent THC exposure, we decided to investigate whether also THC-
induced histone modifications are restricted to the adolescent treatment. This would 
support their involvement in the development of the altered phenotype. To this aim, we 
performed the same treatment and the same time-course study of histone modifications 
in adult female rats exposed to THC. Briefly, female rats were injected with increasing 
doses of THC from 75 to 85 PND and 2, 24 and 48 hours after the last injection, the chosen 
histone modifications were analysed. 
In the hippocampus of adult animals (Fig.9), H3K14ac was significantly increased (67%) 2 
hours after the end of the treatment. This was the only alteration induced by adult THC 
treatment in this cerebral area, as 24 and 48 hours after the last THC injection, no 
significant changes were observed. 
 
Figure 9. Effect of adult THC exposure on histone modifications occurring in the hippocampus of female rats, 2, 24 
and 48 hours after the last THC injection. Data are expressed as mean ± SEM of at least five animals for each 
experimental group. *p<0.05 versus controls (Student’s t-test analysis). 
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In the Nucleus Accumbens (Fig.10), chronic THC administration did not induce significant 
alterations of histone markers 2 and 48 hours after the end of the treatment. However, 
24 hours after the last THC injection a significant increase in H3K14ac (34%) levels was 
observed. 
 
Figure 10. Effect of adult THC exposure on histone modifications occurring in the Nucleus Accumbens of female rats, 
2, 24 and 48 hours after the last THC injection. Data are expressed as mean ± SEM of at least five animals for each 
experimental group. *p<0.05 versus controls (Student’s t-test analysis) 
 
Concerning the Amygdala (Fig.11), both H3K9me2 and H3K27me3 levels were 
significantly decreased  2 hours after the end of THC treatment(31% and 36%, 
respectively), and then returned to control 24 hours later. At this same interval of time, 
H3K9ac was significantly reduced (39%). Lastly, 48 hours after the last THC injection, 
H3K14ac levels were significantly decreased (28%). 
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Figure 11. Effect of adult THC exposure on histone modifications occurring in the Amygdala of female rats, 2, 24 and 
48 hours after the last THC injection. Data are expressed as mean ± SEM of at least five animals for each experimental 
group. *p<0.05 versus controls (Student’s t-test analysis). 
 
To sum up, these data suggest that adult THC exposure induced changes that are 
restricted to just one histone modification occurring within 24 h after the cessation of the 
treatment. The only exception is represented by the amygdala, where changes were 
present in the entire monitored time window. 
 
 
A GLOBAL VIEW ON THE EFFECTS OF THC EXPOSURE ON HISTONE 
MODIFICATIONS 
 
In order to consider as a whole all the data obtained from adolescent and adult rats 
exposed to THC, we analyzed results in treated animals at each time point (i.e., 2, 24 and 
48 hours) by two-way multivariate analysis of variance (MANOVA), considering as 
independent variables the different brain areas and the age (adolescent/adult). Analysis 
of variance (ANOVA) and the Tukey post-hoc test were used to confirm the effects 
obtained via the MANOVAs and highlight significant (and relevant) contrasts. In almost all 
cases, the ANOVA confirmed the findings of the MANOVA. We decided to evidence 
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relevant differences shown by the Tukey post-hoc test in Figures 12–16. In particular, they 
highlight a different response between age groups in the same brain area, or among brain 
areas in the same age group. 
 
 
 
 
 
 
 
 
Figure 12. Comparison of THC effect on H3K9me2 in adolescent (THC ado in black) and adult (THC adu in red) animals 
in the different brain areas. Data are reported as log2 fold. Mean ± SD are shown. * p < 0.05, ** p < 0.01, *** p < 
0.001 (Tukey post-hoc test) 
 
Regarding H3K9me2 (Figure 12), the multivariate analysis revealed that: (i) age (f = 5.05; 
p = 0.035) and the interaction between the age and the brain area (f = 7.4; p = 0.0035) 
had significant main effects 2 h after the end of the treatment; (ii) age (f = 8.2; p = 0.0080) 
and the brain area (f = 6.8; p = 0.0040) had significant effects at 24 h; and (iii) the 
interaction between age and the brain area (f = 3.9; p = 0.031) had significant effects 48 
h after the last injection. 
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Figure 13. Comparison of THC effect on H3K9me3 in adolescent (THC ado in black) and adult (THC adu in red) animals 
in the different brain areas. Data are reported as log2 fold. Mean ± SD are shown. Hippo, hippocampus; NAc, nucleus 
accumbens; Amy, amygdala. 
Regarding H3K9me3 (Fig. 13), the multivariate analysis revealed that age (f=9.5; 
p=0.0047) had significant effects at 24 hours after the end of the treatment. 
 
 
 
 
 
 
 
 
 
Figure 14. Comparison of THC effect on H3K27me3 in adolescent (THC ado in black) and adult (THC adu in red) 
animals in the different brain areas. Data are reported as log2 fold. Mean ± SD are shown. * p < 0.05 (Tukey post-
hoc test) 
Regarding H3K27me3 (Fig. 14), the multivariate analysis revealed that brain area (f=4.03; 
p=0.032) had significant main effects 2 hours after the end of the treatment. 
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Figure 15. Comparison of THC effect on H3K14ac in adolescent (THC ado in black) and adult (THC adu in red) animals 
in the different brain areas. Data are reported as log2 fold. Mean ± SD are shown. * p < 0.05, *** p < 0.001 (Tukey 
post-hoc test). 
Regarding H3K14ac (Fig. 15), the multivariate analysis revealed that: i) age (f= 10.6; 
p=0.0036) and the interaction between the age and the brain area (f=5.8; p=0.0093) had 
significant main effects 2 hours after the end of the treatment; ii) the interaction between 
the age and the brain area (f=6.1; p=0.0063) had significant main effects at 24 hours. 
 
 
 
 
 
 
 
Figure 16. Comparison of THC effect on H3K9ac in adolescent (THC ado in black) and adult (THC adu in red) animals 
in the different brain areas. Data are reported as log2 fold. Mean ± SD are shown. ** p < 0.01, *** p < 0.001 (Tukey 
post-hoc test) 
Regarding H3K9ac (Fig. 16), the multivariate analysis revealed that the brain area (f=8.1; 
p=0.0018) had significant main effects 24 hours after the end of the treatment. 
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ANALYSIS OF THC-INDUCED HISTONE MODIFICATIONS IN 
DIFFERENT BRAIN AREAS OF MALE RATS 
 
In the last years, the gender gap in Cannabis use, usually characterized by greater 
prevalence in men, is narrowing, highlighting the importance of understanding sex and 
gender differences. Interestingly, abused drugs, Cannabis included, impairs behaviour in 
a sex-dependent manner: women develop depression/anxiety, whereas men suffer from 
attention-deficit hyperactivity and anti-social personality disorders. In line with this, we 
have demonstrated that adolescent THC exposure induces a depressive-psychotic-like 
phenotype in adult female rats, and a psychotic-like phenotype in males. Thus, the second 
aim of this thesis is to evaluate whether THC-induced histone modification changes are 
different in male and female animals. If this is the case, they could be part of the 
molecular underpinnings leading to the development of the sex-dependent phenotype. 
To this aim, we performed the same time-course study of histone modifications in 
adolescent male rats exposed to THC. 
In the Prefrontal Cortex of adolescent male rats (Fig.17), THC exposure did not induce any 
significant change in the evaluated histone markers 2, 24 and 48 hours after the last THC 
injection.  
 
 
 
 
 
 
 
Figure 17. Effect of adolescent THC exposure on histone modifications occurring in the Prefrontal Cortex of male 
rats, 2, 24 and 48 hours after the last THC injection. Data are expressed as mean ± SEM of at least eight animals for 
each experimental group.  
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Similarly, in the Hippocampus (Fig.18), adolescent THC exposure did not alter histone 
modifications at any interval of time.  
 
 
 
 
 
 
 
 
 
Figure 18. Effect of adolescent THC exposure on histone modifications occurring in the Hippocampus of male rats, 
2, 24 and 48 hours after the last THC injection. Data are expressed as mean ± SEM of at least eight animals for each 
experimental group.  
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In the Nucleus Accumbens (Fig.19), H3K9me3 was significantly decreased (18%) 2 hours 
after the end of the treatment. On the contrary, this histone modification significantly 
increased over control levels (18%) 24 hours later. No changes were observed at the last 
time point analysed. 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Effect of adolescent THC exposure on histone modifications occurring in the Nucleus Accumbens of male 
rats, 2, 24 and 48 hours after the last THC injection. Data are expressed as mean ± SEM of at least eight animals for 
each experimental group. *p<0.05 versus controls (Student’s t-test analysis). 
?
To summarize, these results suggest that adolescent THC exposure in male rats induces 
histone modification changes only in the Nucleus Accumbens, thus suggesting a sex-
dependent effect on histone markers.
 
 
 
 
 
 
 
 
 
 
    DISCUSSION  
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There is an increasingly widespread diffusion of Cannabis abuse among adolescents, and 
the political debate concerning Cannabis legalisation is emphasizing the need to 
understand the relationship between Cannabis exposure and the development of 
psychiatric disorders later in life. Although many epidemiological studies seem to confirm 
this association, the molecular mechanisms underlying the risk to develop psychiatric 
illness after adolescent THC exposure are still unclear. 
Since epigenetics plays a crucial role in the etiopathogenesis of psychiatric disorders, we 
wanted to investigate whether chronic THC treatment during adolescence could alter 
histone modifications. 
Our results show that chronic THC exposure affects histone modifications in the brain of 
female rats in a region- and age-specific manner. Indeed, THC acts on different targets 
depending on the considered brain area and, remarkably, the adolescent brain generally 
results more sensitive than the adult brain as evidenced by the multivariate analysis. 
From a kinetic point of view, we may describe two different epigenetic effects that 
influence the adolescent brain. The first effect, mainly repressive, is observed 
immediately after the end of the treatment (2-24 hours) and likely represents a direct 
effect of THC exposure. The second one, which is detectable in the next temporal window 
(i.e. from 24 hours on), may represent a homeostatic response to counterbalance THC-
induced repressive effect, since it has an opposite outcome at the transcriptional level. 
Specifically, the primary effect induced by adolescent THC exposure is the negative 
modulation of gene transcription in all the analyzed brain areas, although this is obtained 
through changes in different histone modifications. 
 In the Hippocampus, the primary effect is the reduction of H3K14ac, a marker known for 
promoting gene expression. This is followed by a significant increase in di- and tri-
methylation of H3K9, markers known to repress gene transcription, at 24 hours. 
Regarding the Nucleus Accumbens and the Amygdala, the primary effect is represented 
by the increase of H3K9me, both H3K9me3 and H3K9me2, within 24 hours of the end of 
the treatment. However, in the Nucleus Accumbens, even the significant increase in 
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H3K14 acetylation at 24 hours could represent a primary event. Indeed, increased H3 
acetylation in this brain area has been observed after chronic administration of different 
drugs of abuse (Malvaez et al., 2011; Wang et al., 2010; Levine et al., 2011), suggesting 
that maybe it could be triggered by the activation of the mesolimbic reward circuitry.  
These data join the results we have recently described in the Prefrontal Cortex (Prini et 
al., 2018), where the same adolescent THC exposure in female rats induced an increase 
in H3K9 methylation. Collectively, these data suggest that H3K9me may represent a 
common target affected by THC in different brain areas, whereas the increased 
acetylation described in the Nucleus Accumbens may be due to THC activation of the 
mesolimbic dopaminergic rewarding circuitry. 
This first wave of THC-induced histone changes drives subsequent chromatin 
rearrangements that are, again, area-specific. Indeed, we observed a switch from down 
to up-regulation of H3K14ac levels in the Hippocampus at 24 hours. All the observed 
histone changes were then reported to control 48 hours after the end of the treatment. 
In agreement with these data, several papers support the hypothesis that the 
Hippocampus is able to adapt quickly in response to chronic THC exposure (Hoffman et 
al., 2007; Robert et al., 2003). Indeed, the hippocampus has proved to be the first 
responding area to chronic treatment with THC through a reduction of both density and 
functionality of CB1 receptors, even after the first administration. In the Nucleus 
Accumbens, the enhancements in H3K9 methylation and H3K14 acetylation were 
completely reversed at 48 hours, when a significant reduction was still present. These 
further histone changes suggest the presence of a homeostatic response to the primary 
effect induced by THC in the adolescent brain, as we have previously described in the 
Prefrontal Cortex (Prini et al., 2018). The only exception is represented by the Amygdala, 
in which primary histone modifications were reported to control levels without further 
mechanisms of counterbalance. 
An important finding of this study regards the age-dependency of THC-induced histone 
modifications. Indeed, adult female rats exposed to chronic THC showed a different 
pattern of histone alterations: whilst the primary effect in the adolescent brain was 
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represented by changes leading to transcriptional repression, the one observed after 
adult treatment leads to transcriptional activation. Accordingly, a significant increase in 
H3K14 acetylation was present in the Hippocampus and Nucleus Accumbens respectively 
2 and 24 hours after the end of the adult treatment. Although in very different 
experimental conditions, Bilkei-Gorzo and colleagues have recently reported similar 
opposing effects of THC exposure in the hippocampus of young and mature mice (Bilkei-
Gorzo et al., 2017). Indeed, they have reported increased H3 acetylation after chronic THC 
exposure in mature mice and a trend to decrease in the young animals, thus 
strengthening the hypothesis of an age-dependent effect of THC on histone 
modifications. Regarding the increase in Nucleus Accumbens H3K14 acetylation, this was 
also observed after adolescent treatment, supporting the hypothesis that it may be linked 
to the activation of the mesolimbic rewarding circuit (Malvaez et al., 2011; Wang et al., 
2010; Levine et al., 2011). Consistently, experimental alterations in Nucleus Accumbens 
histone acetylation affect addiction-related behaviours such as place conditioning and 
locomotor responses to psychostimulants (Robison and Nestler, 2011). 
Intriguingly, a more complex picture is present in the adult amygdala. The primary effect 
of THC exposure in the amygdala is represented by a decrease in H3K9 dimethylation and 
H3K27 trimethylation, which leads to transcriptional activation. On the other hand, in 
adolescent animals we have observed an increase in H3K9 methylation that returned to 
control levels within 48 hours. This difference was further validated by the MANOVA 
analysis, which highlighted a significant association between H3K9 di-methylation and the 
adolescent/adult status after 2 hours from the end of the treatment. The univariate 
ANOVA, followed by the Tukey post-hoc test, confirmed this result and evidenced that 
the significance was due to opposite variations in the amygdala. Another distinctive 
feature of the adult amygdala is the presence of a counterbalance event. Indeed, a second 
wave of changes that leads to transcriptional repression, mediated by a decrease in H3 
acetylation, is present 24 and 48 hours after the end of the treatment. This suggests that 
the amygdala is more responsive in adult than adolescent animals. Again, these 
differences were evidenced by the MANOVA with a significant effect of the interaction 
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between the age and the brain area on H3K14ac. The univariate ANOVA confirmed the 
effect of the brain area and the post-hoc test highlighted the difference between 
adolescent amygdala and adult amygdala. Since it has been established that the amygdala 
is activated during exposure to aversive stimuli, functioning as a “behavioural brake” 
(Zald, 2003), the different response between adult and adolescent animals could 
represent the biological bases of the adolescent propensity for risk-taking and novelty-
seeking behaviours. Remarkably, also in adolescent humans, neuroimaging studies have 
shown a weaker involvement of the amygdala, and a greater contribution of the Nucleus 
Accumbens, in response to negative and positive stimuli, compared to adults (Ernst et al., 
2005). This fits well with the triadic model of neurodevelopment (Ernst et al., 2006), 
suggesting that motivated behaviour is mediated by the tension between reward 
(Nucleus Accumbens) and threat (amygdala) systems. According to this model, 
adolescence would be characterized by an imbalance in the tension between reward and 
threat systems in favour of reward. This would explain the increase in reward seeking and 
lower regard for negative consequences that characterize adolescent behaviour. In line 
with this model, our results showed a greater responsiveness of the adolescent Nucleus 
Accumbens and a weaker sensitivity of the amygdala to THC exposure compared to 
adults. 
 
As a whole, these results suggest that in the adolescent brain THC triggers a more complex 
response characterized by a primary effect followed by compensatory changes, except 
for the amygdala. These changes may perturb adolescent brain refinement, thus 
underlying the behavioural alterations observed after adolescent THC (Rubino and 
Parolaro, 2016). The presence of compensatory events may be part of the mechanisms 
that make the female adolescent brain more vulnerable to THC adverse effects. 
However, despite women show an increased susceptibility to developing Cannabis use 
disorder and comorbidities relative to men, we have to consider that men are more likely 
to endorse past month cannabis use and are more frequently diagnosed with Cannabis 
use disorder. Thus, it is important to extend our knowledge on THC-induced histone 
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modifications in males, to better understand whether an epigenetic mechanism may 
contribute to this sex-dependent THC response. 
Our results show that chronic THC exposure affects histone modifications in the brain of 
adolescent male rats in a region-dependent manner.  
Surprisingly, in the Prefrontal Cortex and Hippocampus, adolescent THC exposure did not 
affect the investigated histone modifications. In contrast, in the Nucleus Accumbens, we 
observed immediately after the end of the treatment a decrease in H3K9 trimethylation 
that suggests transcriptional activation. This primary event of transcriptional activation 
was counterbalanced 24 hours later, by a significant enhancement of H3K9 trimethylation 
levels. Alterations in methylation of H3K9 in the Nucleus Accumbens has been already 
described after chronic exposure to different drugs of abuse, such as MDMA (Caputi et 
al., 2016), morphine (Sun et al., 2012), cocaine (Maze et al., 2010), amphetamine and 
methamphetamine (Godino et al., 2015). Since all these drugs have in common the ability 
to activate the mesolimbic dopaminergic system, we may speculate that changes in the 
methylation status of H3K9 could be related to the activation of this circuit. 
In general, the picture observed in male brain is completely different from that observed 
in females. Indeed, THC-induced changes in histone modifications were more intense and 
widespread in female brains.  
These results are quite surprising and different hypotheses could be suggested.  
First of all, we investigated only a subset of histone modifications, thus it could be possible 
that other histone modifications could be affected by THC exposure in adolescent males. 
In the same line, other brain areas could play a major role in THC effects in males. 
Regardless these limitations, our data further highlight the existence of a sex-dependent 
response to THC in adolescent animals.  
Another consideration to take into account is based on results obtained by gene 
expression studies we performed in the prefrontal cortex of adolescent female rats. We 
found that alterations in histone modifications in this brain area mainly affected the 
expression of genes related to neuroplasticity and brain refinement processes. 
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Remarkably, it has been reported that brain developmental trajectories are significantly 
different between males and females, and synaptic refinement appears to occur earlier 
in females (Lenroot et al., 2007; see for review Lenroot and Giedd, 2010). We may 
speculate that during early-mid adolescence (the developmental window we focused on) 
maturational processes are mainly present in the female brain. Thus, THC treatment 
during this specific period might primary impair female brain.  
Finally, another explanation regarding the higher intensity of THC effect on histone 
modifications observed in female rats could be ascribed to different pharmacokinetics in 
the two sexes. Indeed it has been reported that adolescent female rats exhibit 
pronounced metabolism of THC to the still active compound 11-OH-THC compared to 
their male conspecifics, particularly after repeated THC administration (Wiley et al., 
2014). Thus, THC effect could be potentiated by its active metabolite in female 
adolescents. This fact together with the observation that adolescent female rats possess 
more efficient CB1 receptors (Rubino and Parolaro, 2011) suggests that they may be more 
vulnerable to THC effects.  
These findings join few others present in literature regarding epigenetic mechanism 
involvement in long-term consequences of cannabinoid exposure during adolescence. As 
already suggested by Szutorisz and Hurd (2018), we may hypothesize that THC exposure 
can imprint on the epigenetic landscape of adolescent brain developmental trajectories 
and thus alter adult brain functionality via the dysregulation of genes that have important 
neurobiological functions. However, whether adolescent cannabinoid exposure may also 
affect the functionality of other tissues/organs is still an unexplored question. Thus, 
gaining knowledge on if and how epigenetic processes are disrupted by cannabinoids, for 
example in the germline, will be of paramount importance to understand the possibility 
to transmit THC effects from parent to offspring. At this regard, Szutorisz et al (2014) have 
demonstrated that exposure of male and female adolescent rats before mating led to 
behavioural and molecular abnormalities in their unexposed offspring suggesting an 
important role for epigenetic mechanism in the heritability of altered phenotypes.  
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In conclusion, our results suggest that Cannabis abuse during adolescence could impair 
the brain network functionality acting through a mechanism involving histone 
modifications that is characterized by sex-specificity. Further studies are needed to clarify 
the epigenetic landscape in male rats and how it impacts on gene expression, and 
ultimately, on adolescent brain refinement. 
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